Hetero
Hetero receives emergency use nod by DCGI for Covid drug Tocilizumab
Hyderabad/UNI: Hetero, the Hyderabad-based pharma major, announced on Monday that the Drugs Controller General of India (DCGI) has issued approval for restricted use, Emergency Use Authorization (EUA) for the generic version of Tocilizumab in India.
This authorization will enable the medical practitioners to use the generic drug Tocilizumab for the treatment of Covid-19 among hospitalized adults, who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or Extracorporeal Membrane Oxygenation (ECMO).
Dr B. Partha Saradhi Reddy, Chairman, Hetero Group said, "This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the Government to ensure equitable distribution."
Hetero’s TOCIRA (Tocilizumab) will be marketed by its associate company ‘Hetero Healthcare’ in India with the support of its strong distribution network across the country.
Hetero’s Tocilizumab 400mg/20ml is the biosimilar version of Roche’s Actemra/RoActemra ® and will be available from September end.
The company's biologics arm ‘Hetero Biopharma’ will be manufacturing the drug at its dedicated biologics facility at Jadcherla.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
